884 related articles for article (PubMed ID: 16503715)
21. The cost of prostate cancer chemoprevention: a decision analysis model.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1485-9. PubMed ID: 16896037
[TBL] [Abstract][Full Text] [Related]
22. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors.
Cussenot O; Azzouzi AR; Nicolaiew N; Mangin P; Cormier L; Fournier G; Valeri A; Cancel-Tassin G
Eur Urol; 2007 Oct; 52(4):1082-7. PubMed ID: 17448593
[TBL] [Abstract][Full Text] [Related]
23. Prostate cancer chemoprevention: current status and future prospects.
Gupta S
Toxicol Appl Pharmacol; 2007 Nov; 224(3):369-76. PubMed ID: 17189645
[TBL] [Abstract][Full Text] [Related]
24. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice.
Canby-Hagino ED; Thompson IM
Nat Clin Pract Oncol; 2005 May; 2(5):255-61. PubMed ID: 16264961
[TBL] [Abstract][Full Text] [Related]
26. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.
Peters U; Littman AJ; Kristal AR; Patterson RE; Potter JD; White E
Cancer Causes Control; 2008 Feb; 19(1):75-87. PubMed ID: 17943452
[TBL] [Abstract][Full Text] [Related]
27. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
28. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
[TBL] [Abstract][Full Text] [Related]
29. [Nutrition and pharmacological treatment for prevention of prostate cancer].
Segev Y; Nativ O
Harefuah; 2006 Jan; 145(1):47-51, 76-7. PubMed ID: 16450727
[TBL] [Abstract][Full Text] [Related]
30. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
31. Serum lycopene, other carotenoids, and prostate cancer risk: a nested case-control study in the prostate, lung, colorectal, and ovarian cancer screening trial.
Peters U; Leitzmann MF; Chatterjee N; Wang Y; Albanes D; Gelmann EP; Friesen MD; Riboli E; Hayes RB
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):962-8. PubMed ID: 17507623
[TBL] [Abstract][Full Text] [Related]
32. Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer.
Orvieto M; Eggener S
Eur Urol; 2009 May; 55(5):1073-4. PubMed ID: 19200640
[No Abstract] [Full Text] [Related]
33. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapeutic prevention studies of prostate cancer.
Djavan B; Zlotta A; Schulman C; Teillac P; Iversen P; Boccon Gibod L; Bartsch G; Marberger M
J Urol; 2004 Feb; 171(2 Pt 2):S10-3; discussion S13-4. PubMed ID: 14713746
[TBL] [Abstract][Full Text] [Related]
35. Chemoprevention of prostate cancer.
Walsh PC
N Engl J Med; 2010 Apr; 362(13):1237-8. PubMed ID: 20357287
[No Abstract] [Full Text] [Related]
36. Phase III prostate cancer prevention trials: are the costs justified?
Thompson IM; Tangen CM; Klein EA; Lippman SM
J Clin Oncol; 2005 Nov; 23(32):8161-4. PubMed ID: 16278467
[TBL] [Abstract][Full Text] [Related]
37. High-grade prostate cancer and finasteride.
Lebdai S; Bigot P; Azzouzi AR
BJU Int; 2010 Feb; 105(4):456-9. PubMed ID: 19930174
[TBL] [Abstract][Full Text] [Related]
38. Update on chemoprevention of prostate cancer.
Klein EA; Thompson IM
Curr Opin Urol; 2004 May; 14(3):143-9. PubMed ID: 15069304
[TBL] [Abstract][Full Text] [Related]
39. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.
Andriole G; Bostwick D; Civantos F; Epstein J; Lucia MS; McConnell J; Roehrborn CG
J Urol; 2005 Dec; 174(6):2098-104. PubMed ID: 16280736
[TBL] [Abstract][Full Text] [Related]
40. Advances in prostate cancer chemoprevention: a translational perspective.
Nambiar D; Singh RP
Nutr Cancer; 2013; 65 Suppl 1():12-25. PubMed ID: 23682779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]